Eurobio-Scientific SA (ALERS) AI Stock Analysis

• Market Cap: €255.14M
• Dividend Yield: N/A
• Average Volume (3M): 1.38K
• Price to Earnings (P/E): 63.9
• Beta (1Y): -0.38
• Revenue Growth: 19.15%
• EPS Growth: -20.71%
• Country: FR
• Employees: 329
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Devices
• EPS (TTM): 0.40
• Shares Outstanding: 10,248,871
• 10 Day Avg. Volume: 450
• 30 Day Avg. Volume: 1,383
• PEG Ratio: -0.15
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: €28.00 ▲(9.80%Upside)

Eurobio-Scientific SA's overall stock score reflects a balanced view of mixed financial performance and positive technical indicators, though the high P/E ratio suggests the stock might be overvalued. The company's strong equity position provides stability, but declining profitability and cash flow metrics are areas of concern.

Eurobio-Scientific SA Business Overview & Revenue Model

Company Description

Eurobio-Scientific SA (ALERS) is a leading French group specializing in the development, manufacturing, and commercialization of specialty in vitro diagnostics for the healthcare sector. The company offers a comprehensive portfolio of products that cater to various medical fields, including infectious diseases, immunology, and oncology. Eurobio-Scientific is committed to innovation and quality, providing diagnostic solutions that aid in disease detection and management, thereby improving patient care outcomes.

How the Company Makes Money

Eurobio-Scientific SA generates revenue primarily through the sale of its in vitro diagnostic products to healthcare institutions, laboratories, and research organizations. The company's revenue streams are divided into product sales and service offerings, which include diagnostic kits, reagents, and laboratory equipment. Eurobio-Scientific also engages in strategic partnerships and collaborations with research institutes and other biotech companies to expand its product offerings and market reach. Additionally, the company invests in research and development to innovate and enhance its product line, which supports its competitive positioning in the market.

Eurobio-Scientific SA Financial Statement Overview

Summary

Eurobio-Scientific SA exhibits a mixed financial performance. The revenue growth is promising, yet profitability margins and cash flow generation are under pressure. The company's strong equity position and low leverage provide stability, but declining ROE and cash flow metrics highlight areas needing improvement. Overall, the company is in a stable position but should focus on enhancing operational efficiencies and cash flow management.

Income Statement

Eurobio-Scientific SA has demonstrated stable profitability with a Gross Profit Margin of 46.43% and a Net Profit Margin of 2.58% for 2024. The Revenue Growth Rate showed a healthy increase of 18.59% from 2023 to 2024. However, there has been a noticeable decline in EBIT and EBITDA Margins compared to previous years, indicating reduced operational efficiency.

Balance Sheet

The company's balance sheet reflects a strong Equity Ratio of 69.56%, suggesting a solid financial foundation. The Debt-to-Equity Ratio is low at 0.19, indicating conservative leverage. However, the Return on Equity has decreased to 2.24% for 2024, which is a concern for shareholders seeking higher returns.

Cash Flow

Eurobio-Scientific SA's cash flow statement shows a decline in Operating Cash Flow by 37.57% from 2023 to 2024, impacting liquidity. Despite this, the Free Cash Flow to Net Income Ratio remains robust at 3.37, indicating effective cash generation relative to net income. However, the Free Cash Flow Growth Rate is negative, reflecting challenges in maintaining positive free cash flow growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
154.95M	130.65M	152.61M	184.71M	188.86M
	Gross Profit
71.95M	57.49M	65.04M	97.44M	105.61M
	EBIT
13.40M	10.14M	31.04M	71.99M	81.21M
	EBITDA
20.40M	24.55M	40.49M	79.63M	88.57M
	Net Income Common Stockholders
4.00M	4.83M	24.94M	60.54M	73.48M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.07M	89.03M	85.94M	102.39M	65.56M
	Total Assets
257.17M	316.33M	330.42M	209.22M	172.30M
	Total Debt
34.05M	101.33M	113.60M	15.68M	29.70M
	Net Debt
12.28M	52.03M	66.11M	-77.24M	-35.40M
	Total Liabilities
78.31M	141.16M	157.75M	49.00M	64.45M
	Stockholders Equity
178.85M	175.17M	172.34M	159.91M	107.11M
Cash Flow		Free Cash Flow
13.45M	22.71M	39.01M	63.61M	52.02M
	Operating Cash Flow
16.70M	26.77M	41.85M	65.46M	54.31M
	Investing Cash Flow
-10.74M	-318.00K	-141.76M	-5.47M	-3.98M
	Financing Cash Flow
-72.09M	-23.50M	83.53M	-23.30M	7.67M

Eurobio-Scientific SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Positive. The current price of 25.5 is above the 20-day moving average (MA) of 25.17, above the 50-day MA of 24.89, and above the 200-day MA of 25.28, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 56.52 is Neutral, neither overbought nor oversold. The STOCH value of 80.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALERS.

Eurobio-Scientific SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GTT	81 Outperform	€6.11B	17.62	87.21%	3.73%	49.96%	72.43%
IPS	80 Outperform	€1.94B	9.46	13.66%	3.69%	2.13%	29.48%
SAN	76 Outperform	€105.85B	19.54	7.34%	4.40%	-4.62%	2.88%
VIRP	75 Outperform	€2.66B	18.33	14.95%	0.42%	12.07%	20.48%
ALERS	67 Neutral	€255.14M	63.93	2.27%	―	19.15%	-20.71%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%